Men more likely to suffer and die from these 3 common illnesses, reveals study: Here are top findings
A new study revealed that men are more at risk of death from certain chronic medical conditions. The UK-based research found that the three most common illnesses affecting males are hypertension, diabetes, and HIV/AIDS.
The research published in the journal PLOS Medicine found that men were more likely to be exposed to risk factor - such as smoking, while women were more likely to be obese and engage in unsafe sex.
According to the research experts, the study underscores sex-based differences at each step of the "health pathway." The key observations of the report align the developments from previous studies that suggest that fewer men opt for preventive, diagnostic, and treatment services. Notably, women are more likely to get themselves screened, diagnosed and seek treatment in cases such as HIV and COVID-19.
Norms related to masculinity and healthcare financing are reportedly roadblocks in men's path to seek medical care while women were more likely to be concerned about their health and to seek medical intervention.
Co-founder of Global 50/50, Kent Buse said, 'Most of these differences are not explained by sex (biology) alone, but by socially-constructed gender -- highlighting the importance of taking a gender justice approach to reducing health inequities. A gender analysis can help to shape systems of health for all.'
"Males had significantly higher prevalence rates of conditions in 56 per cent of countries for HIV and AIDS, 30 per cent for diabetes, and four per cent for hypertension," the study states.
On medical diagnosis among women, the report said, "Females, on the other hand, had significantly higher prevalence rates of conditions in 14 per cent of countries for HIV and AIDS, five per cent for diabetes, and only in India for hypertension," they wrote.
Altogether, death rates obtained from the Global Burden of Disease (GBD) dataset revealed that mortality was higher among men in 131 countries (64 per cent) for HIV/AIDS, compared to women. For hypertension, death rate was higher among men in 107 countries (53 per cent) and for diabetes (49 per cent) it was on the higher end in 100 countries.
First Published: 4 May 2025, 12:23 PM IST
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
From pimples to peptides: How Gen Z turned the dermatologist into a beauty guru
Dermatology clinics are the new beauty salons. Consumers in urban India are no longer walking into a dermat's office with just eczema, psoriasis or some other chronic skin condition. They are increasingly consulting the dermatologist for everyday skin requirements, from dealing with pimples and dandruff to enhancing the skin texture and glow. The trend is mostly driven by teenagers and young adults, but older people, both women and men, are too seeking expert medical help for skin conditions that previously were managed with home remedies. Last year, Suresh (name changed to protect privacy) rushed to a South Delhi dermatologist, worried about pimples—'Can adults get pimples?' was one of his questions to the doctor. The 41-year-old was anxious that it would affect his looks at social engagements. The treatment cost him ₹20,000. 'The stigma around seeking help for 'non-serious' skin concerns has also faded,' says Bengaluru-based Priyanka Reddy, chief dermatologist and founder of DNA Skin Clinic, who has 556,000 followers on Instagram. People today are far more informed about skin health than they were ever before, thanks to social media, beauty influencers and easy access to medical info online. Live Events Both Indian and international companies have been focusing on science-backed skincare brands for a few years now. From Minimalist, now owned by Unilever, to Cetaphil, CeraVe and Honasa Consumer-owned The Derma Co, many brands are vying for the same section of the skincare market: the young and informed consumer. 'We've seen a noticeable uptick in both age groups (Gen Z and Gen Alpha),' says Chytra Anand, dermatologist and founder of Kosmoderma, a Bengaluru-based chain of dermatology clinics. Evidence-based Self-care 'In fact, teens and young adults now make up nearly 20% of new consultations at our clinics. For the 12–18 age group, the top concern is acne—mostly hormonal and sometimes compounded by lifestyle issues like diet, screen time, and stress. There's a growing interest in skin texture and glow, thanks again to beauty influencers and filter-free selfies,' adds Anand. Young consumers are taking 'picture-perfect' quite literally. According to Alok Malik, president and business head - India Formulations at Glenmark Pharmaceuticals , the rise in dermatologist consultations is not just a medical trend; it reflects a broader shift towards evidence-based self-care. 'We are seeing increased usage, which is intentional and informed adoption, with consumers actively choosing science-backed skincare over cosmetic hype,' he says. Known for brands like Maxrich YU, Episoft, Bontress and La Shield Kids, Glenmark has been pushing the prescription vs OTC line of skincare for years now. It is using a combination of dermatological recommendations and modern retail inclusive of ecommerce to reach the target audience. Dermatologists charge ₹1,000–4,000 or more for a visit in India's major cities. This is just the consultation fee. Chances are the doctor will prescribe serums with active ingredients, moisturisers and face wash—a three-four step routine based on products which would cost another ₹10,000 or more. 'Earlier, people would only see a dermatologist for chronic conditions like acne, eczema, or pigmentation that had persisted for years. Now, even a new pimple, suntan, or mild sensitivity prompts a visit, and rightly so,' adds Reddy. 'Skin is our largest organ, and people are beginning to treat it with the same seriousness they give to diet or fitness.' While this is still a fairly urban phenomenon, market research company Statista estimates India's skin treatments market to reach about $895 million (nearly ₹7,750 crore) this year. More than 64% of the customers of Foxtale, a Mumbai-based skincare startup, are Gen Z and the older edge of Gen Alpha — 'those just stepping into their teenage years', says Romita Mazumdar, its CEO and founder. 'On our website, we've seen a 2x increase in ingredient-specific search terms in the last year alone; terms like 'niacinamide', 'glycolic acid' and 'peptides' are constantly searched,' she says. 'Even parents are encouraging early visits, which is great. I've had 15-year-olds ask if they should combine azelaic acid with niacinamide, and college students worried about barrier repair after using too many actives,' says Anand.
Time of India
4 hours ago
- Time of India
Drug offers 99.9% HIV shield, but Indians will have to wait
Mumbai: A new drug promising 99.9% protection against HIV received approval from the US Food & Drug Administration (FDA) a few days ago, but the city's HIV rights activists are sceptical about its practical impact in India. The main concern stems from the new injectable drug lenacapavir's substantial cost of Rs 24 lakh ($28,218) per person for two injections taken six months apart. Also, NACO (National AIDS Control Organisation) has not fully embraced PrEP (pre-exposure prophylaxis) medications, the category to which lenacapavir belongs. "Our govt distributes condoms to break HIV transmission, it provides antiretroviral therapy drugs to prevent parent-to-child transmission of HIV, but it hasn't ever given PrEP to youngsters who are likely to indulge in high-risk behaviour," said health activist Ganesh Acharya. A couple of years ago, NACO made it mandatory for its counselling centres to disburse information on PrEP. He is alarmed because 75% of the 88% diagnosed with HIV in Mumbai between 2023-24 were in the 15-49 age group that is classified as young. PrEP is available for those seeking treatment in the private sector. PrEP, as a method to prevent HIV transmission before a risky exposure, has been around for almost 12 years. It was widely accepted in developed countries, but India's public health machinery never mentioned it until a few years ago. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo "They set up a committee, then a white paper was brought out that served as a backgrounder for guidelines that were drawn up last year. However, there has been no development since," said a doctor with a public hospital. Dr Ishwar Gilada of the People's Health Organisation (India) said PrEP is the lesser evil compared to HIV transmission. "The govt should distribute PrEP to check the spread of the disease, which has only been increasing in recent years. The total number of HIV-positive people in India increased from 2.2 million to 2.5 million in a few years," he added. The problem is more pronounced in Mumbai, he said, where the number of people with sexually transmitted diseases has been rising. "A recent survey in Mumbai among men who have sex with men found that 60% of them were positive for the human papilloma virus. While gonorrhoea and chlamydia vanished 25 years ago, their numbers are shooting up," said Dr Gilada. PrEP would be the solution, according to him. The govt could adopt a three-tier payment system for PrEP: Charge full cost from those who can afford it, subsidy for some, and free for those who cannot afford medications. Despite efforts, NACO officials were not available for comment. PrEP is not the only HIV-related policy that the govt hasn't acted on. Self-testing HIV kits, for instance, are not allowed in India. "We have self-testing kits for pregnancy, diabetes, and Covid, but policymakers fear about the mental health of people after a positive result in self-testing HIV kits," said Dr Gilada. The same logic is possibly behind the delay with introducing PrEP in the public health system, said a senior doctor, as a section of public health officials fear that giving PrEP would seem like a licence for risky behaviour. However, there is hope that lenacapavir would be available in India sooner rather than later. Bala of Bombay Gay said lenacapavir is a "monumental milestone forward in HIV treatment and prevention," but its pricing makes it inaccessible to Indian patients. "So, we have to wait and see if prices will come down over time," he added. Dr Gilada is positive Indian generic pharma companies licensed by Gilead Sciences can bring lenacapavir injections at below $100 per annum cost and may be rolled out soon. "India can do it," he said. In a statement released a couple of days ago, UNAIDS urged Gilead Lifesciences to drop the price of the new HIV prevention shot.
The Hindu
7 hours ago
- The Hindu
Applications invited for B. ED Special Education- Multiple Disabilities
Applications are invited for a two year course in in Special education – Multiple disabilities offered by Vidya Sagar, a 40-year-old, Chennai-based organisation working with people with disabilities. It is a full time regular course, on completion of which, the graduate can work in a mainstream school or a special school, start their own rehab center, take up Teacher Eligibility Test for government jobs, or do higher studies and get into research. This course is affiliated to the Tamil Nadu Teacher Education University, has the equivalence of General education and is recognised by the Rehabilitation Council of India. To know more, contact 9840035203 or mail hrd@
